{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:06:44Z","timestamp":1761541604853,"version":"3.37.3"},"reference-count":89,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"name":"NIH for the Zimmerman Program","award":["HL081588"],"award-info":[{"award-number":["HL081588"]}]},{"name":"Science Foundation Ireland Principal Investigator","award":["11\/PI\/1066"],"award-info":[{"award-number":["11\/PI\/1066"]}]},{"name":"Health Research Board Investigator Lead Project","award":["ILP-POR-2017"],"award-info":[{"award-number":["ILP-POR-2017"]}]},{"name":"National Children's Research Centre Project","award":["C\/18\/1"],"award-info":[{"award-number":["C\/18\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The biological mechanisms involved in the pathogenesis of type 2 and type 3 von Willebrand disease (VWD) have been studied extensively. In contrast, although accounting for the majority of VWD cases, the pathobiology underlying partial quantitative VWD has remained somewhat elusive. However, important insights have been attained following several recent cohort studies that have investigated mechanisms in patients with type 1 VWD and low von Willebrand factor (VWF), respectively. These studies have demonstrated that reduced plasma VWF levels may result from either (1) decreased VWF biosynthesis and\/or secretion in endothelial cells and (2) pathological increased VWF clearance. In addition, it has become clear that some patients with only mild to moderate reductions in plasma VWF levels in the 30 to 50 IU\/dL range may have significant bleeding phenotypes. Importantly in these low VWF patients, bleeding risk fails to correlate with plasma VWF levels and inheritance is typically independent of the VWF gene. Although plasma VWF levels may increase to\u2009&gt;\u200950 IU\/dL with progressive aging or pregnancy in these subjects, emerging data suggest that this apparent normalization in VWF levels does not necessarily equate to a complete correction in bleeding phenotype in patients with partial quantitative VWD. In this review, these recent advances in our understanding of quantitative VWD pathogenesis are discussed. Furthermore, the translational implications of these emerging findings are considered, particularly with respect to designing personalized treatment plans for VWD patients undergoing elective procedures.<\/jats:p>","DOI":"10.1055\/s-0041-1722864","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:31:57Z","timestamp":1614385917000},"page":"192-200","source":"Crossref","is-referenced-by-count":4,"title":["Toward Personalized Treatment for Patients with Low von Willebrand Factor and Quantitative von Willebrand Disease"],"prefix":"10.1055","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-3313","authenticated-orcid":false,"given":"James S.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Irish Centre for Vascular Biology, School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland"},{"name":"National Coagulation Centre, St. James's Hospital, Dublin, Ireland"},{"name":"National Children's Research Centre, Our Lady's Children's Hospital at Crumlin, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"issue":"13","key":"ref1","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"P J Lenting","year":"2015","journal-title":"Blood"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14078","article-title":"Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia","volume":"26","author":"P L Turecek","year":"2020","journal-title":"Haemophilia"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/jth.13696","article-title":"von Willebrand factor and inflammation","volume":"15","author":"C Kawecki","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2010-01-264507","article-title":"Endothelial von Willebrand factor regulates angiogenesis","volume":"117","author":"R D Starke","year":"2011","journal-title":"Blood"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0037-1607352","article-title":"Emerging roles for von Willebrand factor in cancer cell biology","volume":"44","author":"J M O'Sullivan","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V98.5.1424","article-title":"Localized reduction of atherosclerosis in von Willebrand factor-deficient mice","volume":"98","author":"N Methia","year":"2001","journal-title":"Blood"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood.2019000510","article-title":"The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing","volume":"133","author":"J Ishihara","year":"2019","journal-title":"Blood"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bjc.6605463","article-title":"Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery","volume":"102","author":"M Byrne","year":"2010","journal-title":"Br J Cancer"},{"issue":"19","key":"ref9","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2015-11-636464","article-title":"Emerging roles for hemostatic dysfunction in malaria pathogenesis","volume":"127","author":"J M O'Sullivan","year":"2016","journal-title":"Blood"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2015-07-654921","article-title":"A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria","volume":"127","author":"N O'Regan","year":"2016","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(07)65001-5","article-title":"ABO blood group phenotypes and Plasmodium falciparum malaria: unlocking a pivotal mechanism","volume":"65","author":"M P Loscertales","year":"2007","journal-title":"Adv Parasitol"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/bjh.16749","article-title":"COVID19 coagulopathy in Caucasian patients","volume":"189","author":"H Fogarty","year":"2020","journal-title":"Br J Haematol"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"F W Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"M A Laffan","year":"2014","journal-title":"Br J Haematol"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/bloodadvances.2020002038","article-title":"Low VWF: insights into pathogenesis, diagnosis, and clinical management","volume":"4","author":"J S O'Donnell","year":"2020","journal-title":"Blood Adv"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)","volume":"109","author":"A Goodeve","year":"2007","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.09.025","article-title":"Von Willebrand disease mutation spectrum and associated mutation mechanisms","volume":"159","author":"A de Jong","year":"2017","journal-title":"Thromb Res"},{"issue":"20","key":"ref19","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"V H Flood","year":"2016","journal-title":"Blood"},{"issue":"19","key":"ref20","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood-2014-09-603241","article-title":"von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease","volume":"125","author":"Y V Sanders","year":"2015","journal-title":"Blood"},{"issue":"21","key":"ref21","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"M Lavin","year":"2017","journal-title":"Blood"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"P D James","year":"2007","journal-title":"Blood"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"J Eikenboom","year":"2013","journal-title":"Blood"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"e0161310","DOI":"10.1371\/journal.pone.0161310","article-title":"Diagnostic value of measuring platelet Von Willebrand factor in Von Willebrand disease","volume":"11","author":"A Casonato","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"S L Haberichter","year":"2008","journal-title":"Blood"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V99.1.180","article-title":"Reduced von Willebrand factor survival in type Vicenza von Willebrand disease","volume":"99","author":"A Casonato","year":"2002","journal-title":"Blood"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"G Castaman","year":"2008","journal-title":"Blood"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/jth.12875","article-title":"von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo","volume":"13","author":"O Rawley","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15565","article-title":"von Willebrand factor clearance - biological mechanisms and clinical significance","volume":"183","author":"J M O'Sullivan","year":"2018","journal-title":"Br J Haematol"},{"key":"ref30","first-page":"blood.2020005843","article-title":"The relationship between ABO blood group, von Willebrand factor and primary hemostasis","author":"S Ward","year":"2020","journal-title":"Blood"},{"issue":"15","key":"ref31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2016-04-709436","article-title":"N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance","volume":"128","author":"A Chion","year":"2016","journal-title":"Blood"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/jth.13537","article-title":"N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor","volume":"14","author":"J M O'Sullivan","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref33","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.14471","article-title":"von Willebrand factor sialylation-a critical regulator of biological function","volume":"17","author":"S Ward","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"14","key":"ref34","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2018-09-874636","article-title":"Increased galactose expression and enhanced clearance in patients with low von Willebrand factor","volume":"133","author":"S Aguila","year":"2019","journal-title":"Blood"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2017-06-787853","article-title":"A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance","volume":"131","author":"S E Ward","year":"2018","journal-title":"Blood"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood-2011-08-373605","article-title":"Macrophage LRP1 contributes to the clearance of von Willebrand factor","volume":"119","author":"G Rastegarlari","year":"2012","journal-title":"Blood"},{"issue":"26","key":"ref37","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","article-title":"The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels","volume":"121","author":"N Rydz","year":"2013","journal-title":"Blood"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3324\/haematol.2017.175216","article-title":"Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor","volume":"103","author":"N Wohner","year":"2018","journal-title":"Haematologica"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1172\/JCI96400","article-title":"The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity","volume":"128","author":"L L Swystun","year":"2018","journal-title":"J Clin Invest"},{"issue":"19","key":"ref40","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2012-10-415000","article-title":"Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities","volume":"121","author":"R J Preston","year":"2013","journal-title":"Blood"},{"issue":"15","key":"ref41","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2015-04-512731","article-title":"von Willebrand factor propeptide: biology and clinical utility","volume":"126","author":"S L Haberichter","year":"2015","journal-title":"Blood"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"W L Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"05","key":"ref43","first-page":"630","article-title":"An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease","volume":"96","author":"A Cumming","year":"2006","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref44","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2002-09-2892","article-title":"Von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"J E Sadler","year":"2003","journal-title":"Blood"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2004.00933.x","article-title":"Slippery criteria for von Willebrand disease type 1","volume":"2","author":"J E Sadler","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"14","key":"ref46","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","article-title":"Significant gynecological bleeding in women with low von Willebrand factor levels","volume":"2","author":"M Lavin","year":"2018","journal-title":"Blood Adv"},{"issue":"13","key":"ref47","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1182\/bloodadvances.2020002081","article-title":"The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding","volume":"4","author":"L Srivaths","year":"2020","journal-title":"Blood Adv"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1538-7836.2006.01860.x","article-title":"Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study","volume":"4","author":"P D James","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1538-7836.2006.01823.x","article-title":"Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD","volume":"4","author":"J Eikenboom","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/hematology.2019000065","article-title":"Perioperative management of patients with von Willebrand disease","volume":"2019","author":"J S O'Donnell","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/asheducation-2016.1.683","article-title":"New treatment approaches to von Willebrand disease","volume":"2016","author":"M Lavin","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"08","key":"ref52","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2018-10-844936","article-title":"How I treat low von Willebrand factor levels","volume":"133","author":"M Lavin","year":"2019","journal-title":"Blood"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2516.2004.00886.x","article-title":"Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization","volume":"10","author":"K J Pasi","year":"2004","journal-title":"Haemophilia"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17100","article-title":"The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients","volume":"17","author":"I Roberts","year":"2013","journal-title":"Health Technol Assess"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","article-title":"Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial","volume":"389","author":"W T Collaborators","year":"2017","journal-title":"Lancet"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"g4829","DOI":"10.1136\/bmj.g4829","article-title":"Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety","volume":"349","author":"J Poeran","year":"2014","journal-title":"BMJ"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/hae.12955","article-title":"Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey","volume":"22","author":"J Windyga","year":"2016","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01610.x","article-title":"The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)","volume":"14","author":"A B Federici","year":"2008","journal-title":"Haemophilia"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/hae.12763","article-title":"Practical aspects of DDAVP use in patients with von Willebrand disease undergoing invasive procedures: a European survey","volume":"22","author":"J Windyga","year":"2016","journal-title":"Haemophilia"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-2141.2001.03146.x","article-title":"Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism","volume":"115","author":"J O'Donnell","year":"2001","journal-title":"Br J Haematol"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00001721-200404000-00002","article-title":"Role of the thrombelastograph as an adjunctive test in thrombophilia screening","volume":"15","author":"J O'Donnell","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref62","first-page":"1","article-title":"Elevated plasma factor VIII levels--a novel risk factor for venous thromboembolism","volume":"47","author":"J O'Donnell","year":"2001","journal-title":"Clin Lab"},{"issue":"03","key":"ref63","first-page":"387","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease","volume":"88","author":"M Makris","year":"2002","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial","volume":"122","author":"P M Mannucci","year":"2013","journal-title":"Blood"},{"issue":"17","key":"ref65","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"J C Gill","year":"2015","journal-title":"Blood"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"F Peyvandi","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jth.13294","article-title":"Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms","volume":"14","author":"S Alb\u00e1nez","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/hae.12664","article-title":"Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease","volume":"21","author":"N Rydz","year":"2015","journal-title":"Haemophilia"},{"issue":"07","key":"ref69","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Y V Sanders","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/bloodadvances.2019000992","article-title":"Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy","volume":"4","author":"J C Gill","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"ref71","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/j.1538-7836.2012.04923.x","article-title":"The evolution and value of bleeding assessment tools","volume":"10","author":"N Rydz","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16186","article-title":"How I manage severe von Willebrand disease","volume":"187","author":"F WG Leebeek","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"ref73","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2017-06-742692","article-title":"How I treat type 2B von Willebrand disease","volume":"131","author":"R Kruse-Jarres","year":"2018","journal-title":"Blood"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-08-551960","article-title":"How I treat type 2 variant forms of von Willebrand disease","volume":"125","author":"A Tosetto","year":"2015","journal-title":"Blood"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH10-11-0697","article-title":"Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance","volume":"105","author":"G Castaman","year":"2011","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref76","first-page":"984","article-title":"Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history","volume":"104","author":"A S\u00e1nchez-Luceros","year":"2010","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref77","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"G Castaman","year":"2013","journal-title":"Haematologica"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hae.13881","article-title":"An international survey to inform priorities for new guidelines on von Willebrand disease","volume":"26","author":"M A Kalot","year":"2020","journal-title":"Haemophilia"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/hae.12568","article-title":"Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis","volume":"21","author":"A H James","year":"2015","journal-title":"Haemophilia"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2516.1995.tb00056.x","article-title":"Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature","volume":"1","author":"B H Ramsahoye","year":"1995","journal-title":"Haemophilia"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1471-0528.1998.tb10093.x","article-title":"Pregnancy in women with von Willebrand's disease or factor XI deficiency","volume":"105","author":"R A Kadir","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"04","key":"ref82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/hae.12635","article-title":"Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey","volume":"21","author":"S C Stoof","year":"2015","journal-title":"Haemophilia"},{"issue":"11","key":"ref83","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/bloodadvances.2017005090","article-title":"Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease","volume":"1","author":"M V Ragni","year":"2017","journal-title":"Blood Adv"},{"issue":"05","key":"ref84","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2516.2011.02583.x","article-title":"Presurgical pharmacokinetic analysis of a von Willebrand factor\/factor VIII (VWF\/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery","volume":"17","author":"J Di Paola","year":"2011","journal-title":"Haemophilia"},{"issue":"07","key":"ref85","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","article-title":"von Willebrand factor\/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery","volume":"5","author":"S Lethagen","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"P M Mannucci","year":"2002","journal-title":"Blood"},{"issue":"06","key":"ref87","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2516.2011.02534.x","article-title":"von Willebrand factor\/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease","volume":"17","author":"J C Gill","year":"2011","journal-title":"Haemophilia"},{"issue":"08","key":"ref88","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1046\/j.1538-7836.2003.00359.x","article-title":"Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?","volume":"1","author":"S A Brown","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref89","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"S L Haberichter","year":"2006","journal-title":"Blood"},{"issue":"03","key":"ref90","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/hae.13451","article-title":"Analysis of current perioperative management with Haemate\u00ae P\/Humate P\u00ae in von Willebrand disease: Identifying the need for personalized treatment","volume":"24","author":"H CAM Hazendonk","year":"2018","journal-title":"Haemophilia"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1722864.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T03:55:06Z","timestamp":1697946906000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1722864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":89,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1722864","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"type":"print","value":"0094-6176"},{"type":"electronic","value":"1098-9064"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}